Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZONEGRAN | ADVANZ PHARMA | N-020789 RX | 2000-03-27 | 2 products, RLD, RS |
ZONISADE | Azurity | N-214273 RX | 2022-07-15 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
direct rx | ANDA | 2015-08-12 |
zonegran | New Drug Application | 2024-12-05 |
zonisade | New Drug Application | 2023-03-30 |
zonisamide | ANDA | 2025-05-30 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
epilepsy | EFO_0000474 | D004827 | G40.9 |
partial epilepsies | EFO_0004263 | D004828 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | 1 | — | 1 |
Partial epilepsies | D004828 | EFO_0004263 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Zonisamide |
INN | zonisamide |
Description | Zonisamide is a 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position. It has a role as an anticonvulsant, an antioxidant, a central nervous system drug, a protective agent and a T-type calcium channel blocker. It is a member of 1,2-benzoxazoles and a sulfonamide. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)Cc1noc2ccccc12 |
PDB | — |
CAS-ID | 68291-97-4 |
RxCUI | — |
ChEMBL ID | CHEMBL750 |
ChEBI ID | 10127 |
PubChem CID | 5734 |
DrugBank | DB00909 |
UNII ID | 459384H98V (ChemIDplus, GSRS) |